50637-83-7

Upstream product

• 1590-25-6 1-(6-bromonaphthalen-2-yl)ethanone 
• 1256387-44-6 1-(6-bromo-naphthalen-2-yl)-2-diazo-ethanone 
• 861880-64-0 6-bromo-N-methoxy-N-methyl-2-naphthamide 
• 186581-53-3 diazomethane 
• 87700-60-5 6-bromonaphthalene-2-carbonyl chloride 
• 762-04-9 Diethyl phosphonate 
• 1303533-76-7 2,2-dibromo-1-(6-bromonaphthalen-2-yl)ethanone 
• 5773-80-8 6-bromo-2-naphthoic acid 
• 580-13-2 2-bromonaphthalene 

Downstream Products

• 50637-84-8 (3-Methylphenyl)-(6-brom-2-naphthacyl)-sulfid 
• 50637-82-6 (3-Brom-phenyl)-(6-brom-2-naphthacyl)-sulfid 
• 1315483-08-9 C₁₉H₁₃BrO₃ 
• 1303533-77-8 C₂₅H₂₂BrN₃O₂ 
• 1242087-97-3 C₄₁H₄₂N₆O₄ 
• 1303533-78-9 C₄₁H₄₂N₆O₄ 
• 1318898-49-5 1,1-dimethylethyl (2S,4S)-2-{4-[6-(3,4-diaminophenyl)-2-naphthalenyl]-1H-imidazol-2-yl}-4-methyl-1-pyrrolidinecarboxylate 
• 1318898-60-0 methyl {(1S)-1-[((2S,4S)-2-{5-[6-(2-{(2S,4S)-1-[(2R)-2-(dimethylamino)-2-phenylacetyl]-4-methyl-2-pyrrolidinyl}-1H-imidazol-4-yl)-2-naphthalenyl]-1H-benzimidazol-2-yl}-4-methyl-1-pyrrolidinyl)carbonyl]-2-methylpropyl}carbamate 
• 1318898-75-7 methyl ((1S)-2-methyl-1-{[(2S,3aS,6aS)-2-{5-[6-(2-{(2S,4S)-4-methyl-1-[(2R)-2-phenyl-2-(1-pyrrolidinyl)acetyl]-2-pyrrolidinyl}-1H-imidazol-4-yl)-2-naphthalenyl]-1H-benzimidazol-2-yl}hexahydrocyclopenta[b]pyrrol-1(2H)-yl]carbonyl}propyl)carbamate 

Relevant academic research and scientific papers

NOVEL BENZIMIDAZOLE DERIVATIVES

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

N - heterocyclic compound, intermediate, preparation method, pharmaceutical composition and application (by machine translation)

The invention discloses a N - heterocyclic compound, intermediate, preparation method, pharmaceutical composition and application. The invention of SHP2 N - heterocyclic compound to have high selectivity, can effectively inhibit the cell in the SHP2 downstream signal path ERK phosphorylation level, to tumor cells has very good inhibition activity, it has broad drug development prospects; its preparation method is simple, mild reaction conditions, high yield and purity, after treatment is simple, environmental protection, and is favorable for industrial production. (by machine translation)

HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS

A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

Hepatitis C Virus Inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Discovery of ledipasvir (GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection

A new class of highly potent NS5A inhibitors with an unsymmetric benzimidazole-difluorofluorene-imidazole core and distal [2.2.1]azabicyclic ring system was discovered. Optimization of antiviral potency and pharmacokinetics led to the identification of 39 (ledipasvir, GS-5885). Compound 39 (GT1a replicon EC50 = 31 pM) has an extended plasma half-life of 37-45 h in healthy volunteers and produces a rapid >3 log viral load reduction in monotherapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients. 39 has been shown to be safe and efficacious, with SVR12 rates up to 100% when used in combination with direct-acting antivirals having complementary mechanisms.

SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, D and R2 are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.

ANTIVIRAL COMPOUNDS

The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS

Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R' have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors,in HCV therapy.